Literature DB >> 21719829

Pharmacokinetics of moxidectin in the southern hairy-nosed wombat (Lasiorhinus latifrons).

Clare E Death1, David A Taggart, Desmond B Williams, Robert Milne, David J Schultz, Carlysle Holyoake, Kristen S Warren.   

Abstract

Sarcoptic mange, caused by Sarcoptes scabiei var. wombati, could be a significant threat to populations of southern hairy-nosed wombats (Lasiorhinus latifrons; SHNW) in Australia. Treatment is currently based on the off-label use of various parasiticidal drugs, with limited clinical efficacy trials. Our primary aim was to determine the pharmacokinetic parameters of a macrocyclic lactone, moxidectin, to assist in the development of effective treatment protocols. Pharmacokinetic parameters were determined in four female SHNW following a single subcutaneous injection of 0.2 mg/kg moxidectin. Blood samples were collected for 38 days following injection (August-September 2008), for analysis using liquid chromatography and tandem mass spectrometry. The mean peak plasma concentration occurred at 13.6 hr, with a mean peak plasma level of 98.6 ng/ml. The mean elimination half-life was 5.03 days, resulting in a mean area under the curve of 377 ng.day/ml. The peak plasma moxidectin concentration was higher than that seen in livestock species but the plasma elimination half-life was shorter. This study suggests that a single injection of 0.2 mg/kg moxidectin may not be sufficient to clear a mange infection in this species.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21719829     DOI: 10.7589/0090-3558-47.3.643

Source DB:  PubMed          Journal:  J Wildl Dis        ISSN: 0090-3558            Impact factor:   1.535


  5 in total

1.  The use of Cydectin® by wildlife carers to treat sarcoptic mange in free-ranging bare-nosed wombats (Vombatus ursinus).

Authors:  Julie M Old; Candice J A Skelton; Hayley J Stannard
Journal:  Parasitol Res       Date:  2021-01-13       Impact factor: 2.289

2.  A systematic review of moxidectin as a treatment for parasitic infections in mammalian species.

Authors:  Andrea L Schraven; Hayley J Stannard; Julie M Old
Journal:  Parasitol Res       Date:  2021-02-22       Impact factor: 2.289

3.  Fluralaner as a novel treatment for sarcoptic mange in the bare-nosed wombat (Vombatus ursinus): safety, pharmacokinetics, efficacy and practicable use.

Authors:  Vicky Wilkinson; Kotaro Takano; David Nichols; Alynn Martin; Roz Holme; David Phalen; Kate Mounsey; Michael Charleston; Alexandre Kreiss; Ruth Pye; Elizabeth Browne; Christina Næsborg-Nielsen; Shane A Richards; Scott Carver
Journal:  Parasit Vectors       Date:  2021-01-06       Impact factor: 3.876

4.  Drug dose and animal welfare: important considerations in the treatment of wildlife.

Authors:  Kate Mounsey; Robert J Harvey; Victoria Wilkinson; Kotaro Takano; Julie Old; Hayley Stannard; Leanne Wicker; David Phalen; Scott Carver
Journal:  Parasitol Res       Date:  2022-02-11       Impact factor: 2.383

Review 5.  Pathophysiological and Pharmaceutical Considerations for Enhancing the Control of Sarcoptes scabiei in Wombats Through Improved Transdermal Drug Delivery.

Authors:  Jaskaran Bains; Scott Carver; Susan Hua
Journal:  Front Vet Sci       Date:  2022-06-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.